Global Dialysis & Renal Care Market Outlook, 2031

The global dialysis and renal care industry covers services, equipment, consumables and medicines used to treat chronic kidney disease and kidney failure, including haemodialysis, peritoneal dialysis, kidney transplantation support, and management of chronic kidney disease to slow progression and treat complications such as anaemia and mineral and bone disorders. Kidney failure, also called end-stage kidney disease, requires dialysis or transplantation to survive, and more than four million people worldwide are estimated to receive dialysis or live with a kidney transplant, while chronic kidney disease affects about one in ten adults globally. The market combines dialysis services, delivered mainly in outpatient dialysis clinics, with products including dialysis machines, dialysers, bloodlines, dialysis fluids, catheters and water treatment systems. Fresenius Medical Care, the world's largest dialysis company, operates about 3,700 clinics and makes machines and consumables, while DaVita runs more than 3,000 clinics, mostly in the United States. Other major providers include U.S. Renal Care, American Renal Associates, Diaverum, B. Braun Avitum, NephroPlus in India and many hospital and public dialysis units. Product suppliers include Vantive, the former kidney care business of Baxter sold to Carlyle in 2025, Nipro, Nikkiso, Toray, Medtronic and DaVita's joint venture Mozarc Medical, and Outset Medical. Pharmaceutical companies including AstraZeneca, Boehringer Ingelheim and Eli Lilly, Bayer, Novo Nordisk, Amgen, Vifor within CSL, and Akebia provide drugs for chronic kidney disease and its complications.

Dialysis patients were among the most vulnerable during the pandemic, with high rates of COVID-19 deaths that temporarily reduced the number of US dialysis patients and strained providers already facing nurse shortages. Since then, the industry has been shaped by new treatments that slow kidney disease and by efforts to shift care toward home dialysis and transplantation. SGLT2 inhibitors such as Farxiga and Jardiance were approved to slow chronic kidney disease progression in 2021 and 2023, finerenone was approved for kidney disease in type 2 diabetes, and in October 2023 Novo Nordisk stopped its FLOW trial of semaglutide early because of clear benefit on kidney outcomes, causing dialysis company shares to fall on fears of slower patient growth. The FDA approved Ozempic to reduce kidney disease progression in patients with type 2 diabetes in January 2025. In the United States, the ESRD Treatment Choices model encouraged home dialysis and transplantation, and CMS launched the Increasing Organ Transplant Access Model in July 2025. Corporate changes included Baxter's sale of its kidney care business to Carlyle, completed in January 2025 as Vantive, and a ransomware attack on DaVita in April 2025 that disrupted operations and exposed patient data. Xenotransplantation reached a milestone when the FDA allowed United Therapeutics to begin a clinical trial of gene-edited pig kidney transplants in 2025, following several individual transplants in 2024 and 2025.

Market Dynamics Market Drivers • Rising Prevalence of Diabetes, Hypertension and AgeingDiabetes and hypertension are the leading causes of chronic kidney disease and kidney failure, and their prevalence is rising worldwide, particularly in Asia, the Middle East and Latin America. Ageing populations increase the number of people with declining kidney function. Better survival on dialysis and wider access to treatment in emerging markets increase the number of patients receiving dialysis, supporting long-term demand.
• Expanding Access to Dialysis in Emerging MarketsMany low- and middle-income countries have large numbers of people with kidney failure who cannot access dialysis. Governments in China, India, Southeast Asia, Latin America and the Middle East are expanding coverage, such as India's Pradhan Mantri National Dialysis Programme, which provides free dialysis in public hospitals through public-private partnerships. Private dialysis chains are expanding to meet demand, creating growth opportunities for providers and suppliers.

Market Challenges • Reimbursement Pressure and Workforce ShortagesDialysis providers rely heavily on government payers, such as Medicare in the United States, whose payment rates often rise slowly compared with costs for staff, supplies and technology. Shortages of dialysis nurses and technicians increase labour costs and limit capacity, and some clinics have reduced hours or closed. Commercial insurers pay higher rates in the United States, but efforts to shift dialysis patients from commercial plans to Medicare have been contested in courts.
• Slower Patient Growth from New Kidney-Protective DrugsSGLT2 inhibitors, finerenone and GLP-1 receptor agonists slow the progression of chronic kidney disease, which could reduce or delay the number of patients reaching dialysis over time. Improved management of diabetes and blood pressure also helps. While these trends benefit patients, they may slow growth in dialysis volumes in developed markets, prompting dialysis companies to diversify into kidney care management and value-based care.

Market Trends • Home Dialysis and New TechnologiesHome haemodialysis and peritoneal dialysis offer patients greater flexibility and can improve quality of life, and governments and payers encourage them through payment incentives. Portable and easier-to-use machines, such as Outset Medical's Tablo and systems from Fresenius, Vantive and others, remote patient monitoring and telehealth support home treatment. Research continues on wearable and implantable artificial kidneys, and sorbent-based systems that recycle dialysis fluid.
• Value-Based Kidney Care and TransplantationPayers are moving toward value-based models that reward providers for managing chronic kidney disease, delaying dialysis, coordinating care and increasing transplantation. In the United States, CMS's Kidney Care Choices model and the Increasing Organ Transplant Access Model encourage these goals, and companies such as DaVita, Fresenius, Somatus and Strive Health manage populations of kidney patients. Xenotransplantation and improved organ preservation could expand transplantation in the future.



Segment Analysis Dialysis services account for the largest share of the dialysis and renal care market, while dialysis products, consumables and renal drugs provide significant additional value. Dialysis services, including in-centre haemodialysis, home haemodialysis and peritoneal dialysis support provided by clinics, hospitals and home programmes, account for the largest share of spending, because patients typically receive treatment three times a week for years. Services include nursing care, dietitian and social work support, laboratory testing and medication administration. Dialysis products include haemodialysis machines, peritoneal dialysis cyclers, dialysers, bloodlines, needles, catheters, dialysis concentrates and fluids, and water treatment systems, with Fresenius, Vantive, B. Braun, Nipro, Nikkiso and Toray major suppliers. Consumables are purchased continuously and form a steady revenue stream. Renal drugs include erythropoiesis-stimulating agents and HIF-PH inhibitors for anaemia, intravenous iron, phosphate binders, vitamin D analogues and calcimimetics for mineral and bone disorder, and drugs that slow chronic kidney disease, such as SGLT2 inhibitors, finerenone, ACE inhibitors, angiotensin receptor blockers and semaglutide. Kidney transplantation services and immunosuppressive drugs support patients who receive transplants. Vascular access services, including fistula creation and maintenance, form another segment. Chronic kidney disease management and value-based kidney care services are growing.

Haemodialysis accounts for the large majority of dialysis treatments worldwide, while peritoneal dialysis and home haemodialysis are growing as home-based options. Haemodialysis, in which blood is filtered through a machine and dialyser, is the most common form of dialysis, used by about 90% of dialysis patients in the United States and most patients globally. In-centre haemodialysis is delivered in dialysis clinics or hospitals three times a week for about four hours per session. Haemodiafiltration, which combines diffusion and convection, is widely used in Europe and Japan and gained attention after trials suggested survival benefits. Home haemodialysis allows patients to dialyse at home more frequently or overnight, improving flexibility, though it requires training and support. Peritoneal dialysis uses the lining of the abdomen as a filter and is performed at home daily, either manually or overnight with a cycler, and it is common in Hong Kong, which has a peritoneal dialysis-first policy, Mexico and some other countries. Peritoneal dialysis can be less expensive than in-centre haemodialysis and preserves independence. Continuous renal replacement therapy is used in intensive care units for patients with acute kidney injury. The United States has aimed to increase the share of patients using home dialysis, which has risen but remains a minority.

Dialysis centres account for the largest share of dialysis care, while hospitals and home care settings serve important and growing roles. Standalone dialysis centres, operated by companies such as Fresenius Medical Care, DaVita, U.S. Renal Care, Diaverum and NephroPlus, deliver most outpatient haemodialysis in the United States and many other countries, and the market is highly concentrated, with Fresenius and DaVita treating most US dialysis patients. Hospital-based dialysis units are the main providers in many countries with public health systems, including much of Europe, Japan and emerging markets, and they also treat acute kidney injury and complex patients. Home care settings, including home haemodialysis and peritoneal dialysis, are growing with support from payers, technology improvements and patient preference, and dialysis providers operate home training programmes. Nursing homes increasingly offer on-site dialysis for residents. Transplant centres manage evaluation, surgery and follow-up for kidney transplant patients. Nephrology practices manage chronic kidney disease before dialysis and oversee dialysis care. Public-private partnership dialysis centres, such as those under India's national dialysis programme, provide free or subsidised dialysis in public hospitals operated by private companies.

Government payers fund the largest share of dialysis and renal care worldwide, while private insurance is important in the United States and out-of-pocket payments limit access in many emerging markets. Government payers fund most dialysis worldwide, because kidney failure treatment is life-sustaining and expensive. In the United States, Medicare covers most people with kidney failure regardless of age under a special programme created in 1972, and Medicare Advantage plans have been allowed to enrol dialysis patients since 2021. National health systems and social insurance in Europe, Japan, Taiwan and elsewhere fund dialysis. Private insurance in the United States pays much higher rates than Medicare during the first 30 months of dialysis for commercially insured patients, providing a large share of dialysis company profits. Government schemes in emerging markets, including India's national dialysis programme, China's national health insurance and Mexico's public health system, are expanding coverage. Out-of-pocket payments remain a major barrier in many low- and middle-income countries, where many patients cannot afford dialysis and die or stop treatment. Charitable organisations and religious groups fund dialysis in some countries. Value-based arrangements, including Medicare's kidney care models, reward providers for outcomes such as home dialysis, transplantation and reduced hospitalisation.

Regional Analysis North America leads the dialysis and renal care market by value because of high dialysis spending in the United States and the presence of the largest dialysis providers, while Asia-Pacific has the largest dialysis patient population and the fastest growth. North America, led by the United States, accounts for the largest share of dialysis and renal care spending. The United States has more than 550,000 dialysis patients, Medicare coverage for kidney failure, a highly concentrated dialysis market led by DaVita and Fresenius Medical Care, and high commercial payment rates. Policy changes, including the ESRD Treatment Choices model, the Kidney Care Choices model and the Increasing Organ Transplant Access Model from 2025, aim to increase home dialysis and transplantation, while the approval of Ozempic for kidney disease in 2025 and wider use of SGLT2 inhibitors may slow future dialysis growth. DaVita's 2025 ransomware attack highlighted cybersecurity risks. Canada provides dialysis through public health systems. Europe is a large market with high use of haemodiafiltration, hospital-based and private dialysis providers such as Fresenius, B. Braun Avitum and Diaverum, and public funding. Asia-Pacific has the largest number of dialysis patients, driven by China, Japan, India, Taiwan and South Korea. Japan and Taiwan have among the highest rates of dialysis per person in the world, China's dialysis population has grown rapidly with expanded insurance coverage, and India's national dialysis programme has increased access through public-private partnerships, though many patients remain untreated. Latin America, led by Brazil and Mexico, has large dialysis populations, with Mexico relying heavily on peritoneal dialysis. The Middle East has high rates of diabetes-related kidney failure, and Africa has very limited access to dialysis.

Key Developments July 2025: CMS began a mandatory payment model for selected kidney transplant hospitals to increase the number of transplants and reduce organ discards.
April 2025: DaVita reported a ransomware attack that encrypted parts of its network and exposed data of patients, although dialysis treatments continued.
February 2025: The FDA allowed United Therapeutics to begin a clinical trial of gene-edited pig kidney transplants in patients with kidney failure.
January 2025: Semaglutide was approved to reduce the risk of kidney failure, disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
January 2025: Baxter completed the sale of its kidney care business to Carlyle for about USD 3.8 billion, creating Vantive as a standalone dialysis products company.
October 2023: Novo Nordisk halted its FLOW kidney outcomes trial of semaglutide early after an interim analysis showed clear benefit, causing dialysis company shares to fall.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Dialysis & Renal Care Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Offering
• Dialysis Services
• Dialysis Products and Consumables
• Renal Drugs
• Transplant and Kidney Care Management

By Dialysis Type
• In-Centre Haemodialysis
• Home Haemodialysis
• Peritoneal Dialysis
• Continuous Renal Replacement Therapy

By End User
• Dialysis Centres
• Hospitals
• Home Care Settings
• Nursing Homes

By Payer
• Government Payers
• Private Insurance
• Out-of-Pocket Payments